DOCSLIB.ORG

IMW 2019 Aminopeptidase Gene Expression Poster

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Poster FP-028 Aminopeptidase Gene Expression in Myeloma Nina Nupponen,1 Muntasir Majumder,2 Paul Dowling,3 Juha Lievonen,4 Despina Bazou,5 Ana Slipicevic,1 Raija Silvennoinen,4 Pekka Anttila,4 Peter O`Gorman,5 Fredrik Lehmann,1 and Caroline A. Heckman6 1Oncopeptides AB, Stockholm, Sweden; 2Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland; 3Maynooth University, Dublin, Ireland; 4Department of Hematology, Helsinki University Hospital and Comprehensive Cancer Center, Helsinki, Finland; 5Mater Misericordiae University Hospital, Dublin, Ireland; 6Helsinki University Hospital Cancer Center, Helsinki, Finland INTRODUCTION RESULTS A hallmark of myeloma is high-level production • Aminopeptidase gene expression levels were ranked based on abundance levels in all • We also investigated whether any aminopeptidase could be linked to disease progression and • Ex vivo testing of patient cells with the • Survival analysis revealed patient samples exhibiting 2× or higher LAP3 of immunoglobulins leading to a heavy load on samples (Figure 1A) found no significant difference (Figure 2) aminopeptidase inhibitor tosedostat showed expression had poorer prognosis with a median survival of 6 months that the viability of approximately 30% of from the sampling date (P=0.0001, HR 4.5; 95% CI 1.45-14.05) ( ) protein folding and homeostasis in tumor cells. Aminopeptidases were differentially expressed compared to heathy plasma cells - Expression levels of LAP3, ERAP1, METAP2, and DPP7 (P>0.005) appeared higher in Figure 5 • relapsed myeloma samples was reduced The aminopeptidase gene family catalyze the (Figure 1B) relapsed/refractory multiple myeloma (RRMM) than in newly diagnosed multiple myeloma hydrolysis of amino acid residues from proteins (NDMM) samples (Figure 4) - The majority of the genes in patient samples showed related expression patterns or Figure 5. LAP3 Expression Is Associated With Poor Prognosis or peptides and are last in line for protein - RNA expression of LAP3, DPP3, METAP1D, were modestly overexpressed (DPP7, DPP3, METAP2 and LAP3) compared to healthy - A comparison of expression levels in 6 paired NDMM and RRMM samples showed a trend for degradation. They are thus an important group CTSV, TPP2, and XNPEP1 was found to 1.0 LAP3+ (n=18) plasma cells increased LAP3 at relapse of metalloenzymes implicated in cellular significantly correlate with tosedostat Others (n=48) functions such as differentiation, cell cycle, - Decreased expression was detected for several aminopeptidases including MMP14, response (Spearman P<0.005) 0.8 DNA repair, and apoptosis. However, there is MMP15, ANPEP, ENPEP, and CTSH Figure 2. Gene Expression Changes During Disease Progression - The figure demonstrates LAP3 and DDP3 limited information about the expression of RNA expression in relation to tosedostat aminopeptidases in myeloma and their possible LAP3 ERAP1 METAP2 DPP7 LAP3 0.6 Figure 1. Gene Expression Profiles of Aminopeptidases 400 50 100 100 100 ns treatment utilization for novel therapeutic approaches 300 60 80 including peptide conjugated drugs. A Abundant Modestly Expressed Low or No Housekeeping Genes 200 40 50 80 0.4 Aminopeptidases Aminopeptidases Expression (n=17) 100 60 Figure 4. Inhibition of Aminopeptidases 10 50 30 40 50 60 6 0.2 8 40 30 40 P=0.0001 20 40 METHODS 6 30 30 Hazard Ratio 4.5 20 4 20 20 0.0 10 20 103 bone marrow aspirates from myeloma 10 0 4 8 12 16 20 24 2 Expression (RPKM) 10 10 4 patients and 2 healthy donors were obtained 0 0 0 0 0 0 Survival (months) after written informed consent and following -2 approved protocols in compliance with -4 NDMMRRMM NDMMRRMM NDMMRRMM NDMMRRMM 2 the Declaration of Helsinki. CD138+ cells At Relapse -6 LAP3 were enriched and used for RNA or protein At Diagnosis CONCLUSIONS -8 Healthy CD138+ Healthy CD138+ Healthy CD138+ Healthy CD138+ preparation. Illumina-compatible RNA -10 sequencing libraries were prepared and Expression (Log2 RPKM) Association of prior exposure to treatments with LAP3 expression was analyzed in the patients -12 • 0 • The majority of aminopeptidase genes in myeloma sequenced. Proteomic analysis was performed (Figure 3) using Q-Exactive MS/Dionex Ultimate 3000 -14 patient samples showed similar expression patterns - Here, we compared expression between samples exposed and naïve to melphalan, TC AP2 TBP instruments. Contribution of aminopeptidase LAP3 TPP2 A4H AP1D VRN PGK1 P value 0.0007 or were modestly overexpressed compared to DPP7ERAP1AMZ2 STX16DPP3DPP8 BLMHPEPD DPP9 CTSH DPP4 PHEXL CTSV DPP6RPL19 ACTB TUBBLDHA CL SDHAGUSBALAS1 HPRT1 G6PD ERAP2 LT LNPEP RNPEP DNPEP C9orf3ANPEPENPEP MMP17TRHDE RPLP0 ABCF1 MET NPEPPS NPEPL1 MMP14 MMP16 MMP15 GAPDH POLR2APOLR1B XPNPEP1 METXPNPEP3RNPEPL1 XPNPEP2 bortezomib class, or immunomodulatory drugs (IMIDs) gene expression to survival outcome Genes -2 healthy plasma cells was estimated by Kaplan-Meier analysis. - Elevated expression of LAP3 was detected in all treated groups (melphalan P=0.01, 0 10 20 30 40 Significance of survival curves between B bortezomib P=0.04, and IMIDs P=0.04) DPP7, DPP3, METAP2, and LAP3 were most 4 3 • 2 groups (high vs. normal expression) was frequently expressed in this sample set deduced using a log rank test (Mantel-Cox). Figure 3. LAP3 Expression Underlying Disease Progression 2 2 Melphalan Bortezomib IMiDs • LAP3 was identified as a potential poor prognostic 0 4 4 4 4 marker for myeloma P=0.01 P=0.04 P=0.04 1 -2 Ex vivo treatment of myeloma patient CD138+ cells 2 2 2 2 • DPP3 with the aminopeptidase inhibitor tosedostat -4 0 results in cell death and thus strengthens the role -6 0 0 0 0 of these genes in myeloma biology LAP3 Expression -1 -8 Fold Change (Log2) P=0.05 Expression Fold Change (Log2) -2 -2 -2 -2 P value <0.0001 -10 -2 Naive AP2 AP1D LAP3 A4H TPP2 VRN DPP7DPP3 DPP9ERAP1 AMZ2 BLMHDPP8 DPP6 PEPDSTX16 CTSV L CTSHPHEX DPP4 Exposed Exposed Exposed Sensitive Alkylator 0 10 20 30 40 Copies of this poster obtained through Quick Response (QR) Code are for DNPEP RNPEP ERAP2 LT C9orf3 LNPEP MMP17 MMP16 NPEPL1MMP15 ANPEPTRHDE MMP14ENPEP Treatment XPNPEP1 MET RNPEPL1NPEPPS Refractory Refractory MET XPNPEP3 XPNPEP2 Bortezomib Bortezomib+ Not Exposed Not Exposed Not Exposed Tosedostat Drug Sensitivity Score personal use only and may not be reproduced without permission from the Len RefractoryLen Refractory Genes author of this poster. Presented at the 17th International Myeloma Workshop; September 12-15; Boston, Massachusetts..
Recommended publications
  • Functional Proteomic Profiling of Secreted Serine Proteases In

    Functional Proteomic Profiling of Secreted Serine Proteases In

    www.nature.com/scientificreports OPEN Functional Proteomic Profling of Secreted Serine Proteases in Health and Infammatory Bowel Disease Received: 24 November 2017 Alexandre Denadai-Souza1, Chrystelle Bonnart1, Núria Solà Tapias1, Marlène Marcellin2, Accepted: 30 April 2018 Brendan Gilmore3, Laurent Alric4, Delphine Bonnet1, Odile Burlet-Schiltz2, Morley D. Hollenberg5, Published: xx xx xxxx Nathalie Vergnolle1,5 & Céline Deraison1 While proteases are essential in gastrointestinal physiology, accumulating evidence indicates that dysregulated proteolysis plays a pivotal role in the pathophysiology of infammatory bowel disease (IBD). Nonetheless, the identity of overactive proteases released by human colonic mucosa remains largely unknown. Studies of protease abundance have primarily investigated expression profles, not taking into account their enzymatic activity. Herein we have used serine protease-targeted activity- based probes (ABPs) coupled with mass spectral analysis to identify active forms of proteases secreted by the colonic mucosa of healthy controls and IBD patients. Profling of (Pro-Lys)-ABP bound proteases revealed that most of hyperactive proteases from IBD secretome are clustered at 28-kDa. We identifed seven active proteases: the serine proteases cathepsin G, plasma kallikrein, plasmin, tryptase, chymotrypsin-like elastase 3 A, and thrombin and the aminopeptidase B. Only cathepsin G and thrombin were overactive in supernatants from IBD patient tissues compared to healthy controls. Gene expression analysis highlighted the transcription of genes encoding these proteases into intestinal mucosae. The functional ABP-targeted proteomic approach that we have used to identify active proteases in human colonic samples bears directly on the understanding of the role these enzymes may play in the pathophysiology of IBD. Te degradome represents almost 2% of protein coding genes in the human genome, with at least 588 genes cod- ing for proteases.
  • Supplementary Materials: Evaluation of Cytotoxicity and Α-Glucosidase Inhibitory Activity of Amide and Polyamino-Derivatives of Lupane Triterpenoids

    Supplementary Materials: Evaluation of Cytotoxicity and Α-Glucosidase Inhibitory Activity of Amide and Polyamino-Derivatives of Lupane Triterpenoids

    Supplementary Materials: Evaluation of cytotoxicity and α-glucosidase inhibitory activity of amide and polyamino-derivatives of lupane triterpenoids Oxana B. Kazakova1*, Gul'nara V. Giniyatullina1, Akhat G. Mustafin1, Denis A. Babkov2, Elena V. Sokolova2, Alexander A. Spasov2* 1Ufa Institute of Chemistry of the Ufa Federal Research Centre of the Russian Academy of Sciences, 71, pr. Oktyabrya, 450054 Ufa, Russian Federation 2Scientific Center for Innovative Drugs, Volgograd State Medical University, Novorossiyskaya st. 39, Volgograd 400087, Russian Federation Correspondence Prof. Dr. Oxana B. Kazakova Ufa Institute of Chemistry of the Ufa Federal Research Centre of the Russian Academy of Sciences 71 Prospeсt Oktyabrya Ufa, 450054 Russian Federation E-mail: [email protected] Prof. Dr. Alexander A. Spasov Scientific Center for Innovative Drugs of the Volgograd State Medical University 39 Novorossiyskaya st. Volgograd, 400087 Russian Federation E-mail: [email protected] Figure S1. 1H and 13C of compound 2. H NH N H O H O H 2 2 Figure S2. 1H and 13C of compound 4. NH2 O H O H CH3 O O H H3C O H 4 3 Figure S3. Anticancer screening data of compound 2 at single dose assay 4 Figure S4. Anticancer screening data of compound 7 at single dose assay 5 Figure S5. Anticancer screening data of compound 8 at single dose assay 6 Figure S6. Anticancer screening data of compound 9 at single dose assay 7 Figure S7. Anticancer screening data of compound 12 at single dose assay 8 Figure S8. Anticancer screening data of compound 13 at single dose assay 9 Figure S9. Anticancer screening data of compound 14 at single dose assay 10 Figure S10.
  • The Global Architecture Shaping the Heterogeneity and Tissue-Dependency of the MHC Class I Immunopeptidome Is Evolutionarily Conserved

    The Global Architecture Shaping the Heterogeneity and Tissue-Dependency of the MHC Class I Immunopeptidome Is Evolutionarily Conserved

    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.28.317750; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The Global Architecture Shaping the Heterogeneity and Tissue-Dependency of the MHC Class I Immunopeptidome is Evolutionarily Conserved Authors Peter Kubiniok†1, Ana Marcu†2,3, Leon Bichmann†2,4, Leon Kuchenbecker4, Heiko Schuster1,5, David Hamelin1, Jérome Despault1, Kevin Kovalchik1, Laura Wessling1, Oliver Kohlbacher4,7,8,9,10 Stefan Stevanovic2,3,6, Hans-Georg Rammensee2,3,6, Marian C. Neidert11, Isabelle Sirois1, Etienne Caron1,12* Affiliations *Corresponding and Leading author: Etienne Caron ([email protected]) †Equal contribution to this work 1CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada 2Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Baden-Württemberg, 72076, Germany. 3Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Baden-Württemberg, 72076, Germany. 4Applied Bioinformatics, Dept. of Computer Science, University of Tübingen, Tübingen, Baden- Württemberg, 72074, Germany. 5Immatics Biotechnologies GmbH, Tübingen, 72076, Baden-Württemberg, Germany. 6DKFZ Partner Site Tübingen, German Cancer Consortium (DKTK), Tübingen, Baden- Württemberg, 72076, Germany. 7Institute for Bioinformatics and Medical Informatics,
  • Structure of Human Aspartyl Aminopeptidase Complexed With

    Structure of Human Aspartyl Aminopeptidase Complexed With

    Chaikuad et al. BMC Structural Biology 2012, 12:14 http://www.biomedcentral.com/1472-6807/12/14 RESEARCH ARTICLE Open Access Structure of human aspartyl aminopeptidase complexed with substrate analogue: insight into catalytic mechanism, substrate specificity and M18 peptidase family Apirat Chaikuad1, Ewa S Pilka1, Antonio De Riso2, Frank von Delft1, Kathryn L Kavanagh1, Catherine Vénien-Bryan2, Udo Oppermann1,3 and Wyatt W Yue1* Abstract Backround: Aspartyl aminopeptidase (DNPEP), with specificity towards an acidic amino acid at the N-terminus, is the only mammalian member among the poorly understood M18 peptidases. DNPEP has implicated roles in protein and peptide metabolism, as well as the renin-angiotensin system in blood pressure regulation. Despite previous enzyme and substrate characterization, structural details of DNPEP regarding ligand recognition and catalytic mechanism remain to be delineated. Results: The crystal structure of human DNPEP complexed with zinc and a substrate analogue aspartate-β- hydroxamate reveals a dodecameric machinery built by domain-swapped dimers, in agreement with electron microscopy data. A structural comparison with bacterial homologues identifies unifying catalytic features among the poorly understood M18 enzymes. The bound ligands in the active site also reveal the coordination mode of the binuclear zinc centre and a substrate specificity pocket for acidic amino acids. Conclusions: The DNPEP structure provides a molecular framework to understand its catalysis that is mediated by active site loop swapping, a mechanism likely adopted in other M18 and M42 metallopeptidases that form dodecameric complexes as a self-compartmentalization strategy. Small differences in the substrate binding pocket such as shape and positive charges, the latter conferred by a basic lysine residue, further provide the key to distinguishing substrate preference.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Elucidation of the Function of Type 1 Human Methionine Aminopeptidase During Cell Cycle Progression

    Elucidation of the Function of Type 1 Human Methionine Aminopeptidase During Cell Cycle Progression

    Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progression Xiaoyi Hu*, Anthony Addlagatta†, Jun Lu*, Brian W. Matthews†‡, and Jun O. Liu*‡§ *Department of Pharmacology and Molecular Sciences and §Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205; and †Institute of Molecular Biology, Howard Hughes Medical Institute and Department of Physics, University of Oregon, Eugene, OR 97403-1229 Contributed by Brian W. Matthews, October 4, 2006 (sent for review September 7, 2006) Processing of the N-terminal initiator methionine is an essential notion that HsMetAP2 plays an important role in endothelial cell cellular process conserved from prokaryotes to eukaryotes. The proliferation and is likely to mediate inhibition of endothelial cells enzymes that remove N-terminal methionine are known as methi- by fumagillin and related analogs (5, 6, 9). onine aminopeptidases (MetAPs). Human MetAP2 has been shown In contrast to HsMetAP2, little is known about the physiological to be required for the proliferation of endothelial cells and angio- function of human MetAP1, although genetic studies in yeast have genesis. The physiological function of MetAP1, however, has suggested a more dominant role for ScMetAP1, as evidenced by the remained elusive. In this report we demonstrate that a family of more severe growth defect observed in ScMetAP1 knockout strain inhibitors with a core structure of pyridine-2-carboxylic acid pre- than that in ScMetAP2 knockout strain (10). There has also been viously developed for the bacterial and yeast MetAP1 is also circumstantial evidence implicating a role of HsMetAP1 in tumor specific for human MetAP1 (HsMetAP1), as confirmed by both cell proliferation.
  • Differential Proteomic Analysis of the Pancreas of Diabetic Db/Db Mice Reveals the Proteins Involved in the Development of Complications of Diabetes Mellitus

    Differential Proteomic Analysis of the Pancreas of Diabetic Db/Db Mice Reveals the Proteins Involved in the Development of Complications of Diabetes Mellitus

    Int. J. Mol. Sci. 2014, 15, 9579-9593; doi:10.3390/ijms15069579 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article Differential Proteomic Analysis of the Pancreas of Diabetic db/db Mice Reveals the Proteins Involved in the Development of Complications of Diabetes Mellitus Victoriano Pérez-Vázquez 1,*, Juan M. Guzmán-Flores 1, Daniela Mares-Álvarez 1, Magdalena Hernández-Ortiz 2, Maciste H. Macías-Cervantes 1, Joel Ramírez-Emiliano 1 and Sergio Encarnación-Guevara 2 1 Depto. de Ciencias Médicas, División de Ciencias de la Salud, Campus León, Universidad de Guanajuato, León, Guanajuato 37320, Mexico; E-Mails: [email protected] (J.M.G.-F.); [email protected] (D.M.-A.); [email protected] (M.H.M.-C.); [email protected] (J.R.-E.) 2 Centro de Ciencias Genómicas, Universidad Nacional Autónoma de México, Cuernavaca, Morelos 62210, Mexico; E-Mails: [email protected] (M.H.-O.); [email protected] (S.E.-G.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +52-477-7143-812; Fax: +52-477-7167-623. Received: 4 April 2014; in revised form: 14 May 2014 / Accepted: 19 May 2014 / Published: 30 May 2014 Abstract: Type 2 diabetes mellitus is characterized by hyperglycemia and insulin-resistance. Diabetes results from pancreatic inability to secrete the insulin needed to overcome this resistance. We analyzed the protein profile from the pancreas of ten-week old diabetic db/db and wild type mice through proteomics. Pancreatic proteins were separated in two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and significant changes in db/db mice respect to wild type mice were observed in 27 proteins.
  • Mitochondrial Protein Quality Control Mechanisms

    Mitochondrial Protein Quality Control Mechanisms

    G C A T T A C G G C A T genes Review Mitochondrial Protein Quality Control Mechanisms Pooja Jadiya * and Dhanendra Tomar * Center for Translational Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA * Correspondence: [email protected] (P.J.); [email protected] (D.T.); Tel.: +1-215-707-9144 (D.T.) Received: 29 April 2020; Accepted: 15 May 2020; Published: 18 May 2020 Abstract: Mitochondria serve as a hub for many cellular processes, including bioenergetics, metabolism, cellular signaling, redox balance, calcium homeostasis, and cell death. The mitochondrial proteome includes over a thousand proteins, encoded by both the mitochondrial and nuclear genomes. The majority (~99%) of proteins are nuclear encoded that are synthesized in the cytosol and subsequently imported into the mitochondria. Within the mitochondria, polypeptides fold and assemble into their native functional form. Mitochondria health and integrity depend on correct protein import, folding, and regulated turnover termed as mitochondrial protein quality control (MPQC). Failure to maintain these processes can cause mitochondrial dysfunction that leads to various pathophysiological outcomes and the commencement of diseases. Here, we summarize the current knowledge about the role of different MPQC regulatory systems such as mitochondrial chaperones, proteases, the ubiquitin-proteasome system, mitochondrial unfolded protein response, mitophagy, and mitochondria-derived vesicles in the maintenance of mitochondrial proteome and health. The proper understanding of mitochondrial protein quality control mechanisms will provide relevant insights to treat multiple human diseases. Keywords: mitochondria; proteome; ubiquitin; proteasome; chaperones; protease; mitophagy; mitochondrial protein quality control; mitochondria-associated degradation; mitochondrial unfolded protein response 1. Introduction Mitochondria are double membrane, dynamic, and semiautonomous organelles which have several critical cellular functions.
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
  • Methionine Aminopeptidase Emerging Role in Angiogenesis

    Methionine Aminopeptidase Emerging Role in Angiogenesis

    Chapter 2 Methionine Aminopeptidase Emerging role in angiogenesis Joseph A. Vetro1, Benjamin Dummitt2, and Yie-Hwa Chang2 1Department of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Ave., Lawrence, KS 66047, USA. 2Edward A. Doisy Department of Biochemistry and Molecular Biology, St. Louis University Health Sciences Center, 1402 S. Grand Blvd., St. Louis, MO 63104, USA. Abstract: Angiogenesis, the formation of new blood vessels from existing vasculature, is a key factor in a number of vascular-related pathologies such as the metastasis and growth of solid tumors. Thus, the inhibition of angiogenesis has great potential as a therapeutic modality in the treatment of cancer and other vascular-related diseases. Recent evidence suggests that the inhibition of mammalian methionine aminopeptidase type 2 (MetAP2) catalytic activity in vascular endothelial cells plays an essential role in the pharmacological activity of the most potent small molecule angiogenesis inhibitors discovered to date, the fumagillin class. Methionine aminopeptidase (MetAP, EC 3.4.11.18) catalyzes the non-processive, co-translational hydrolysis of initiator N-terminal methionine when the second residue of the nascent polypeptide is small and uncharged. Initiator Met removal is a ubiquitous and essential modification. Indirect evidence suggests that removal of initiator Met by MetAP is important for the normal function of many proteins involved in DNA repair, signal transduction, cell transformation, secretory vesicle trafficking, and viral capsid assembly and infection. Currently, much effort is focused on understanding the essential nature of methionine aminopeptidase activity and elucidating the role of methionine aminopeptidase type 2 catalytic activity in angiogenesis. In this chapter, we give an overview of the MetAP proteins, outline the importance of initiator Met hydrolysis, and discuss the possible mechanism(s) through which MetAP2 inhibition by the fumagillin class of angiogenesis inhibitors leads to cytostatic growth arrest in vascular endothelial cells.
  • The Tumor Suppressor Notch Inhibits Head and Neck Squamous Cell

    The Tumor Suppressor Notch Inhibits Head and Neck Squamous Cell

    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2015 THE TUMOR SUPPRESSOR NOTCH INHIBITS HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) TUMOR GROWTH AND PROGRESSION BY MODULATING PROTO-ONCOGENES AXL AND CTNNAL1 (α-CATULIN) Shhyam Moorthy Shhyam Moorthy Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Biochemistry, Biophysics, and Structural Biology Commons, Cancer Biology Commons, Cell Biology Commons, and the Medicine and Health Sciences Commons Recommended Citation Moorthy, Shhyam and Moorthy, Shhyam, "THE TUMOR SUPPRESSOR NOTCH INHIBITS HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) TUMOR GROWTH AND PROGRESSION BY MODULATING PROTO-ONCOGENES AXL AND CTNNAL1 (α-CATULIN)" (2015). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 638. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/638 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. THE TUMOR SUPPRESSOR NOTCH INHIBITS HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) TUMOR GROWTH AND PROGRESSION BY MODULATING PROTO-ONCOGENES AXL AND CTNNAL1 (α-CATULIN) by Shhyam Moorthy, B.S.
  • Arxiv:2007.15681V2 [Cs.CL] 9 Nov 2020 Method by a Large Margin

    Arxiv:2007.15681V2 [Cs.CL] 9 Nov 2020 Method by a Large Margin

    COVID-19 therapy target discovery with context-aware literature mining Matej Martinc1;2, Blaˇz Skrljˇ 1;2, Sergej Pirkmajer3, Nada Lavraˇc1;2;4, Bojan Cestnik5;1, Martin Marzidovˇsek1;2, and Senja Pollak2 1 JoˇzefStefan International Postgraduate School, Ljubljana, Slovenia 2 JoˇzefStefan Institute, Ljubljana, Slovenia 3 Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia 4 University of Nova Gorica, Vipava, Slovenia 5 Temida d.o.o, Ljubljana, Slovenia The final reviewed publication was published in Proceedings of the 23rd International Conference on Discovery Science (DS 2020), Thessaloniki, Greece, October 19{21, 2020 and is available online at https://doi.org/ 10.1007/978-3-030-61527-7 8. Abstract. The abundance of literature related to the widespread COVID- 19 pandemic is beyond manual inspection of a single expert. Develop- ment of systems, capable of automatically processing tens of thousands of scientific publications with the aim to enrich existing empirical evidence with literature-based associations is challenging and relevant. We propose a system for contextualization of empirical expression data by approxi- mating relations between entities, for which representations were learned from one of the largest COVID-19-related literature corpora. In order to exploit a larger scientific context by transfer learning, we propose a novel embedding generation technique that leverages SciBERT language model pretrained on a large multi-domain corpus of scientific publications and fine-tuned for domain adaptation on the CORD-19 dataset. The con- ducted manual evaluation by the medical expert and the quantitative evaluation based on therapy targets identified in the related work suggest that the proposed method can be successfully employed for COVID-19 therapy target discovery and that it outperforms the baseline FastText arXiv:2007.15681v2 [cs.CL] 9 Nov 2020 method by a large margin.